Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN83495 vs megestrol acetate in advanced or recurrent endometrial cancer
2009-010613-68Phase 2Completed
- Sponsor
- Ipsen
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irosustat in endometrial cancer (EC) (2 arms), sponsored by Ipsen. Primary endpoint: 6‑month non-progression and survival. Started Apr 2009; status: completed.
02
Drugs
irosustat
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2009-010613-68.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010613-68.